A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma. 

The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented in the second half of 2025. 

EsoBiotec CEO Jean-Pierre Latere commented: “There are different types of treatments available for patients with multiple myeloma, including ex vivo CAR-T options, but many are associated with debilitating side effects and patient access remains limited by manufacturing capacity, logistical complexity, and high costs. We are keen to explore the safety and efficacy of ESO-T01 in this study, and we believe the results could allow expansion to other indications including autoimmune diseases.” 

In preclinical studies, a single injection of ESO-T01 demonstrated potent anti-tumour activity against cancer cells in humanised mice.  

These studies showed highly effective in vivo transduction, with the BCMA CAR transgene specifically expressed in T cells. This led to the generation of a large population of circulating BCMA CAR-T cells, which persisted throughout the study, highlighting their long-term durability and efficacy. 

EsoBiotec Chief Scientific Officer Philippe Parone added: “This innovative approach delivers high specificity and efficient transduction in vivo due to the unique design features of our ENaBL technology. When this technology is combined with a robust, scalable, and reproducible manufacturing process, ESO-T01 represents an opportunity to provide patients with a cost-effective, off-the-shelf therapy, redefining access to advanced therapies.” 

He added: “EsoBiotec has been operating in stealth mode and has raised €22M in a challenging funding environment thanks to the support of very committed investors including Thuja Capital, UCB Ventures, Invivo Partners, Wallonie Entreprendre (WE), SambrInvest and Investsud.”

Diana Spencer, Senior Digital Content Editor, DDW